DOXAZOSIN MESYLATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for doxazosin mesylate and what is the scope of freedom to operate?
Doxazosin mesylate
is the generic ingredient in three branded drugs marketed by Viatris, Accord Hlthcare, Actavis Elizabeth, Ani Pharms, Apotex, Aurobindo Pharma Usa, Chartwell Rx, Genpharm, Heritage Pharma, Ivax Sub Teva Pharms, Nesher Pharms, Pliva, Rising, Strides Pharma, Teva, Unichem, Upsher Smith Labs, Watson Labs Inc, and Zydus Pharms, and is included in twenty-one NDAs. Additional information is available in the individual branded drug profile pages.There are fourteen drug master file entries for doxazosin mesylate. Thirty-two suppliers are listed for this compound.
Summary for DOXAZOSIN MESYLATE
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 19 |
| NDAs: | 21 |
| Drug Master File Entries: | 14 |
| Finished Product Suppliers / Packagers: | 32 |
| Raw Ingredient (Bulk) Api Vendors: | 106 |
| Clinical Trials: | 2 |
| Patent Applications: | 3,011 |
| Drug Prices: | Drug price trends for DOXAZOSIN MESYLATE |
| What excipients (inactive ingredients) are in DOXAZOSIN MESYLATE? | DOXAZOSIN MESYLATE excipients list |
| DailyMed Link: | DOXAZOSIN MESYLATE at DailyMed |
Recent Clinical Trials for DOXAZOSIN MESYLATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | |
| Pfizer | |
| University of Minnesota - Clinical and Translational Science Institute | Phase 2 |
Pharmacology for DOXAZOSIN MESYLATE
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Medical Subject Heading (MeSH) Categories for DOXAZOSIN MESYLATE
Anatomical Therapeutic Chemical (ATC) Classes for DOXAZOSIN MESYLATE
US Patents and Regulatory Information for DOXAZOSIN MESYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accord Hlthcare | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 202824-004 | Jun 11, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Watson Labs Inc | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075426-002 | Oct 18, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Nesher Pharms | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075609-001 | Oct 18, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ivax Sub Teva Pharms | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 075453-004 | Oct 18, 2000 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Rising | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 212727-004 | Mar 15, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Accord Hlthcare | DOXAZOSIN MESYLATE | doxazosin mesylate | TABLET;ORAL | 202824-003 | Jun 11, 2014 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DOXAZOSIN MESYLATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viatris | CARDURA XL | doxazosin mesylate | TABLET, EXTENDED RELEASE;ORAL | 021269-002 | Feb 22, 2005 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-003 | Nov 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-004 | Nov 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-002 | Nov 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Viatris | CARDURA | doxazosin mesylate | TABLET;ORAL | 019668-001 | Nov 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
